open access

Vol 27, No 3 (2020)
Technology note — Interventional cardiology
Published online: 2020-05-20
Get Citation

Atrial flow regulator as a novel therapy for patients with chronic heart failure

Łukasz Lewicki, Robert Sabiniewicz, Janusz Siebert, Marek Szołkiewicz
DOI: 10.5603/CJ.a2020.0077
·
Pubmed: 32436584
·
Cardiol J 2020;27(3):309-311.

open access

Vol 27, No 3 (2020)
Technology note — Interventional cardiology
Published online: 2020-05-20

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

atrial flow regulator, heart failure, interatrial shunting

About this article
Title

Atrial flow regulator as a novel therapy for patients with chronic heart failure

Journal

Cardiology Journal

Issue

Vol 27, No 3 (2020)

Pages

309-311

Published online

2020-05-20

DOI

10.5603/CJ.a2020.0077

Pubmed

32436584

Bibliographic record

Cardiol J 2020;27(3):309-311.

Keywords

atrial flow regulator
heart failure
interatrial shunting

Authors

Łukasz Lewicki
Robert Sabiniewicz
Janusz Siebert
Marek Szołkiewicz

References (9)
  1. Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018; 39(30): 2780–2792.
  2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32(6): 670–679.
  3. Ewert P, Berger F, Nagdyman N, et al. Masked left ventricular restriction in elderly patients with atrial septal defects: a contraindication for closure? Catheter Cardiovasc Interv. 2001; 52(2): 177–180.
  4. Bruch L, Winkelmann A, Sonntag S, et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J Interv Cardiol. 2008; 21(1): 44–49.
  5. Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010; 121(9): 1086–1095.
  6. Shah SJ, Feldman T, Ricciardi MJ, et al. One-Year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol. 2018; 3(10): 968–977.
  7. Paitazoglou C, Özdemir R, Pfister R, et al. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention. 2019; 15(5): 403–410.
  8. Dąbrowska-Kugacka A, Ciećwierz D, Żuk G, et al. Atrial flow regulator for severe drug resistant pulmonary arterial hypertension after congenital heart defect correction. Cardiol J. 2019; 26(1): 102–104.
  9. Janus M, Sławek-Szmyt S, Araszkiewicz A, et al. Atrial flow regulator as a bridge to lung transplantation in a young patient with drug-resistant idiopathic pulmonary arterial hypertension. Kardiol Pol. 2020 [Epub ahead of print].

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl